Categories Earnings, Health Care, LATEST

PetMed (PETS) Q3 earnings drop but beat Street view; sales miss

Earnings of PetMed Express Inc. (NASDAQ: PETS) decreased in the third quarter even as net sales remained unchanged. The bottom line, however, exceeded the market’s expectations.

Net income dropped to $6.8 million or $0.34 per share in the third quarter from $7.7 million or $0.38 per share a year earlier. Earnings, however, exceeded analysts’ forecast. At $59.9 million, net sales were broadly flat year-over-year but below the market’s expectations.

Order Growth

During the three-month period, the average order size edged up to $85 from $84 last year. Reorder sales increased 1% annually to $53.8 million.

Related: PetMed Q2 Earnings Conference Call Transcript

The management’s successful efforts to establish direct purchasing relationships with leading manufacturers and the implementation of minimum advertised price policy have translated into margin growth. Total operating expenses decreased 2% to $9.8 million.

Competition

Of late, the company has been focused on marketing and promotional activities as it continues to face stiff competition from rival pet pharmacy Chewy (CHWY). Last month, Chewy reported a net loss for its third quarter, despite an increase in sales. The bottom line was impacted by higher operating expenses.

“In 2020, we will focus on optimizing our marketing in this more competitive environment and being more efficient with our advertising spending. In addition, we will continue investing in our e-commerce platform to better service our customers. This platform will enable us to improve upon our already strong net promoter score of 84.0%.“ said PetMed’s CEO Menderes Akdag.

Dividend

In the third quarter, PetMed’s board of directors declared a quarterly cash dividend of $0.27 per share, which will be paid on February 14, 2020, to shareholders of record on February 3, 2020.

Also read: Retail space gets busy as firms see new opportunities

Last week, PetMed shares climbed to the highest level in twelve months. The stock closed the last trading session notably higher but traded lower during Tuesday’s premarket trading hours. Since the beginning of the year, it gained about 17%.

Listen to publicly listed companies’ earnings conference calls along with the edited closed caption text

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top